Home Newsfeeds Guggenheim Upgrades Immunovant to Buy

Guggenheim Upgrades Immunovant to Buy

Guggenheim analyst Yatin Suneja upgrades Immunovant (NASDAQ:IMVT) from Neutral to Buy.

byBenzinga Newsdesk

February 13, 2023

1 minute read

Guggenheim analyst Yatin Suneja upgrades Immunovant (NASDAQ:IMVT) from Neutral to Buy.

Needham Maintains Buy on MACOM Technology Solns, Raises Price Target to $68

By Benzinga Newsdesk

November 4, 5:36 AM

Needham analyst Quinn Bolton maintains MACOM Technology Solns (NASDAQ:MTSI) with a Buy and raises the price target from $62 to $68.

MTSI

Barrington Research Reiterates Outperform on Cumulus Media, Lowers Price Target to $11

By Benzinga Newsdesk

February 27, 1:42 PM

Barrington Research analyst James Goss reiterates Cumulus Media (NASDAQ:CMLS) with a Outperform and lowers the price target from $14 to $11.

CMLS

Silicon Valley Bank Creditors Purchased Bonds At Distressed Levels Anticipating Potential Bankruptcy Sale

By Vandana Singh

March 15, 11:41 AM

Silicon Valley Bank's parent, SVB Financial Group's (NASDAQ: SIVB) creditors, have formed a group in the case of a potential bankruptcy filing.

PJT

MicroVision Unveils New MOVIA Sensor And Wins Order For Legacy Sensor, Financial Terms Not Disclosed; Sees Q1 Revenue Of $400K-$500K

By Happy Mohamed

April 5, 9:23 AM

MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and advanced driver-assistance systems (ADAS) solutions, today announced the launch of its solid-state flash-based MOVIA lidar sensor.

MVIS

Guggenheim Upgrades Immunovant to Buy

Related Posts

Needham Maintains Buy on MACOM Technology Solns, Raises Price Target to $68

Barrington Research Reiterates Outperform on Cumulus Media, Lowers Price Target to $11

Silicon Valley Bank Creditors Purchased Bonds At Distressed Levels Anticipating Potential Bankruptcy Sale

MicroVision Unveils New MOVIA Sensor And Wins Order For Legacy Sensor, Financial Terms Not Disclosed; Sees Q1 Revenue Of $400K-$500K